Periostin, a novel biomarker of TH2-driven asthma

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 1, 2014, Pages 60-65

  Parulekar, Amit D ^a   Atik, Mustafa A ^a   Hanania, Nicola A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

asthma; periostin; TH2 inflammation

Indexed keywords

EOTAXIN; FASCICLIN I; FLUTICASONE; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEBRIKIZUMAB; OMALIZUMAB; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA;

ASPERGILLUS FUMIGATUS; ASTHMA; BRONCHUS BIOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; LUNG FUNCTION; LUNG LAVAGE; MACROPHAGE ACTIVATION; NONHUMAN; PHENOTYPE; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ASTHMA; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; CELL ADHESION MOLECULES; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TH2 CELLS; TREATMENT OUTCOME;

EID: 84890117435     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000005     Document Type: Review

References (50)

1. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004; 59:469-478
2. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008; 38:872-897
3. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med 2004; 10:44-50
4. Gibson PG. Inflammatory phenotypes in adult asthma: Clinical applications. Clin Respir J 2009; 3:198-206
5. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224
6. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323
7. Siddiqui S, Brightling CE. Airways disease: Phenotyping heterogeneity using measures of airway inflammation. Allergy Asthma Clin Immunol 2007; 3:60-69
8. Wenzel SE. Asthma: Defining of the persistent adult phenotypes. Lancet 2006; 368:804-813
9. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2012; 18:716-725
10. A plea to abandon asthma as a disease concept [editorial]. Lancet 2006; 368:705
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95
12. Cazzola M, Novelli G. Biomarkers in COPD. Pulm Pharmacol Ther 2010; 23:493-500
13. Diamant Z, Boot JD, Mantzouranis E, et al. Biomarkers in asthma and allergic rhinitis. Pulm Pharmacol Ther 2010; 23:468-481
14. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41:347-366
15. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6:543-545
16. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-Driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395
17. Diamant Z, Tufvesson E, Bjermer L. Which biomarkers are effective for identifying Th2-Driven inflammation in asthmä Curr Allergy Asthma Rep 2013; 13:477-486
18. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012; 130:829-842
19. Van Der Pouw Kraan TC, Van Der Zee JS, Boeije LC, et al. The role of IL-13 in IgE synthesis by allergic asthma patients. Clin Exp Immunol 1998; 111:129-135
20. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779-788
21. Besnard AG, Togbe D, Guillou N, et al. IL-33-Activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol 2011; 41:1675-1686
22. Ramirez-Icaza G, Mohammed KA, Nasreen N, et al. Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells. J Clin Immunol 2004; 24:426-434
23. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem 2011; 286:1786-1794
24. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med 1975; 292:1152-1155
25. PopeSM, Brandt EB, Mishra A, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5-And eotaxin-Dependent mechanism. J Allergy Clin Immunol 2001; 108:594-601
26. Kuperman DA, Huang X, Koth LL, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002; 8:885-889
27. Chibana K, Trudeau JB, Mustovich AT, et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells. Clin Exp Allergy 2008; 38:936-946
28. Venkayya R, Lam M, Willkom M, et al. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002; 26:202-208
29. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104:15858-15863
30. Yuyama N, Davies DE, Akaiwa M, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine 2002; 19:287-296
31. Lopez-Guisa JM, Powers C, File D, et al. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol 2012; 129:990-997
32. Takayama G, Arima K, Kanaji T, et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118:98-104
33. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-Derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107:14170-14175
34. Norris RA, Damon B, Mironov V, et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 2007; 101:695-711
35. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: Cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993; 294 (Pt 1):271-278
36. Kruzynska-Frejtag A, Machnicki M, Rogers R, et al. Periostin (an osteoblastspecific factor) is expressed within the embryonic mouse heart during valve formation. Mech Dev 2001; 103:183-188
37. Snider P, Hinton RB, Moreno-Rodriguez RA, et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res 2008; 102:752-760
38. Kudo Y, Siriwardena BS, Hatano H, et al. Periostin: Novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007; 22:1167-1174
39. Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008; 1:289-296
40. Gordon ED, Sidhu SS, Wang ZE, et al. A protective role for periostin and TGFbeta in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy 2012; 42:144-155
41. Sehra S, Yao W, Nguyen ET, et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol 2011; 186:4959-4966
42. Masuoka M, Shiraishi H, Ohta S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 2012; 122:2590-2600
43. Bhakta NR, Solberg OD, Nguyen CP, et al. A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy 2013; 3:24
44. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130:647-654
45. Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013; 132:305-312
46. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-1098
47. Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013; 132:567-574
48. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med 2011; 154:573-582
49. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804-811
50. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: Biomarkers. J Allergy Clin Immunol 2012; 129:S9-S23